# Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)

Source: https://onco.cc/trials/nct07255612/  
OnCo record `nct07255612` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of trilaciclib and eribulin in triple-negative breast cancer, run by Sun Yat-sen University, not yet recruiting.

## Summary

Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer) is a phase 2, interventional study registered as NCT07255612 by Sun Yat-sen University, with a registry enrolment figure of 29 participants, started 2026-11-04 and due to reach its primary completion in 2026-12-01. Interventions recorded: Trilaciclib; Eribulin. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "locally advanced or metastatic triple-negative breast cancer;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07255612
- Phase: 2
- Setting: A Single-arm, Phase II Study for Bone Marrow Protection, Safety, and Efficacy of Trilaciclib Combined With Eribulin in Locally Advanced or Metastatic Triple-negative Breast Cancer After at Least Two Prior Chemotherapy Regimens
- Sponsor: Sun Yat-sen University
- Enrolled: 29

## Sources

- ClinicalTrials.gov NCT07255612: https://clinicaltrials.gov/study/NCT07255612

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Eribulin](https://onco.cc/drugs/eribulin/), [Trilaciclib](https://onco.cc/drugs/trilaciclib/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07255612.json